The immune-stimulating peptide WKYMVm has therapeutic effects against ulcerative colitis

Experimental and Molecular Medicine

Volumn 45, Issue 9, 2013, Pages

  Kim, Sang Doo ^a,b   Kwon, Soonil ^a,b   Lee, Sung Kyun ^a,b   Kook, Minsoo ^a,b   Lee, Ha Young ^a,b   Song, Ki Duk ^c   Lee, Hak Kyo ^c   Baek, Suk Hwan ^d   Park, Chan Bae ^b,e   Bae, Yoe Sik ^a,b  

^a Sungkyunkwan University   (South Korea)

^b Dong A University   (South Korea)

^c Hankyong National University   (South Korea)

^d Yeungnam University College of Medicine   (South Korea)

^e Ajou University School of Medicine   (South Korea)

Author keywords

Therapeutics; Ulcerative colitis; WKYMVm

Indexed keywords

DEXTRAN SULFATE; FORMYLPEPTIDE RECEPTOR; FORMYLPEPTIDE RECEPTOR 2; FORMYLPEPTIDE RECEPTOR BLOCKING AGENT; GAMMA INTERFERON; IMMUNOMODULATING AGENT; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 6; PEPTIDE WKYMVM; RECEPTOR BLOCKING AGENT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; FORMYL PEPTIDE RECEPTOR 2, MOUSE; IMMUNOLOGICAL ADJUVANT; OLIGOPEPTIDE; TRP-LYS-TYR-MET-VAL-MET; TRYPTOPHYL-ARGINYL-TRYPTOPHYL-TRYPTOPHYL-TRYPTOPHYL-TRYPTOPHANAMIDE; TRP LYS TYR MET VAL MET; TRYPTOPHYL ARGINYL TRYPTOPHYL TRYPTOPHYL TRYPTOPHYL TRYPTOPHANAMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; COLON MUCOSA; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG TARGETING; EPITHELIUM CELL; FECES ANALYSIS; HUMAN; HUMAN CELL; IMMUNOMODULATION; INTESTINAL BLEEDING; INTESTINE MUCOSA PERMEABILITY; MOUSE; NONHUMAN; ULCERATIVE COLITIS; WEIGHT REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CACO 2 CELL LINE; COLITIS, ULCERATIVE; COLON; DRUG EFFECTS; GENETICS; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; PERMEABILITY; CELL STRAIN CACO 2; DRUG ANTAGONISM; DRUG EFFECT;

MUS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CACO-2 CELLS; CELL PROLIFERATION; COLITIS, ULCERATIVE; COLON; HUMANS; INTERLEUKIN-23; INTESTINAL MUCOSA; MICE; MICE, INBRED C57BL; OLIGOPEPTIDES; PERMEABILITY; RECEPTORS, FORMYL PEPTIDE; TRANSFORMING GROWTH FACTOR BETA;

EID: 84885140842     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2013.77     Document Type: Article

References (35)

1. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature 2007; 448: 427-434
2. Baumgart DC, Carding SR. Inflammatory bowel disease: Cause and immunobiology. Lancet 2007; 369: 1627-1640
3. Economou M, Pappas G. New global map of Crohn's disease: Fenetic, environmental, and socioeconomic correlations. Inflamm Bowel Dis 2008; 14: 709-720
4. Saleh M, Trinchieri G. Innate immune mechanisms of colitis and colitisassociated colorectal cancer. Nat Rev Immunol 2011; 11: 9-20
5. Cho JH. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008; 8: 458-466
6. Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Crohn's disease: Beyond antagonists of tumour necrosis factor. Lancet 2008; 372: 67-81
7. Baek SH, Seo JK, Chae CB, Suh PG, Ryu SH. Identification of the peptides that stimulate the phosphoinositide hydrolysis in lymphocyte cell lines from peptide libraries. J Biol Chem 1996; 271: 8170-8175
8. Seo JK, Choi SY, Kim Y, Baek SH, Kim KT, Chae CB et al. A peptide with unique receptor specificity: Stimulation of phosphoinositide hydrolysis and induction of superoxide generation in human neutrophils. J Immunol 1997; 158: 1895-1901
9. Le Y, Gong W, Li B, Dunlop NM, Shen W, Su SB et al. Utilization of two seven-transmembrane, G protein-coupled receptors, formyl peptide receptor- like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation. J Immunol 1999; 163: 6777-6784
10. Christophe T, Karlsson A, Dugave C, Rabiet MJ, Boulay F, Dahlgren C. The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J Biol Chem 2001; 276: 21585-21593
11. He R, Tan L, Browning DD, Wang JM, Ye RD. The synthetic peptide Trp- Lys-Tyr-Met-Val-D-Met is a potent chemotactic agonist for mouse formyl peptide receptor. J Immunol 2000; 165: 4598-4605
12. Bae YS, Ju SA, Kim JY, Seo JK, Baek SH, Kwak JY et al. Trp-Lys-Tyr-Met- Val-D-Met stimulates superoxide generation and killing of Staphylococcus aureus via phospholipase D activation in human monocytes. J Leukoc Biol 1999; 65: 241-248
13. Bae YS, Kim Y, Kim Y, Kim JH, Suh PG, Ryu SH. Trp-Lys-Tyr-Met-Val-DMet is a chemoattractant for human phagocytic cells. J Leukoc Biol 1999; 66: 915-922
14. Lee HY, Kang HK, Jo EJ, Kim JI, Lee YN, Lee SH et al. Trp-Lys-Tyr-Met-Val- Met stimulates phagocytosis via phospho-lipase D-dependent signaling in mouse dendritic cells. Exp Mol Med 2004; 36: 135-144
15. Kim SD, Kim JM, Jo SH, Lee HY, Lee SY, Shim JW et al. Functional expression of formyl peptide receptor family in human NK cells. J Immunol 2009; 183: 5511-5517
16. Bae YS, Song JY, Kim Y, He R, Ye RD, Kwak JY et al. Differential activation of formyl peptide receptor signaling by peptide ligands. Mol Pharmacol 2003; 64: 841-847
17. Kim SD, Kim YK, Lee HY, Kim YS, Jeon SG, Baek SH et al. The agonists of formyl peptide receptors prevent development of severe sepsis after microbial infection. J Immunol 2010; 185: 4302-4310
18. Gewirtz AT, Collier-Hyams LS, Young AN, Kucharzik T, Guilford WJ, Parkinson JF et al. Lipoxin a4 analogs attenuate induction of intestinal epithelial proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced colitis. J Immunol 2002; 168: 5260-5267
19. Wenzel-Seifert K, Grünbaum L, Seifert R. Differential inhibition of human neutrophil activation by cyclosporins A, D, and H. Cyclosporin H is a potent and effective inhibitor of formyl peptide-induced superoxide formation. J Immunol 1991; 147: 1940-1946
20. Bae YS, Lee HY, Jo EJ, Kim JI, Kang HK, Ye RD et al. Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling. J Immunol 2004; 173: 607-614
21. Teshima CW, Dieleman LA, Meddings JB. Abnormal intestinal permeability in Crohn's disease pathogenesis. Ann NY Acad Sci 2012; 1258: 159-165
22. Salim SY, So?derholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis 2011; 17: 362-381
23. Chen K, Liu M, Liu Y, Yoshimura T, Shen W, Le Y et al. Formylpeptide receptor-2 contributes to colonic epithelial homeostasis, inflammation, and tumorigenesis. J Clin Invest 2013; 123: 1694-1704
24. Babbin BA, Jesaitis AJ, Ivanov AI, Kelly D, Laukoetter M, Nava P et al. Formyl peptide receptor-1 activation enhances intestinal epithelial cell restitution through phosphatidylinositol 3-kinase-dependent activation of Rac1 and Cdc42. J Immunol 2007; 179: 8112-8121
25. Kucharzik T, Gewirtz AT, Merlin D, Madara JL, Williams IR. Lateral membrane LXA4 receptors mediate LXA4's anti-inflammatory actions on intestinal epithelium. Am J Physiol Cell Physiol 2003; 284: C888-C896
26. Sarra M, Pallone F, Macdonald TT, Monteleone G. IL-23/IL-17 axis in IBD. Inflamm Bowel Dis 2010; 16: 1808-1813
27. Monteleone I, Pallone F, Monteleone G. The interleukin-23 axis in intestinal inflammation. Immunol Rev 2008; 226: 147-159
28. Shull MM, Ormsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M et al. Targeted disruption of the mouse transforming growth factor-beta 1 gene results in multifocal inflammatory disease. Nature 1992; 359: 693-699
29. Kulkarni AB, Ward JM, Yaswen L, Mackall CL, Bauer SR, Huh CG et al. Transforming growth factor-beta 1 null mice. An animal model for inflammatory disorders. Am J Pathol 1995; 146: 264-275
30. Gorelik L, Flavell RA. Abrogation of TGFbeta signaling in T cells leads to spontaneous T cell differentiation and autoimmune disease. Immunity 2000; 12: 171-181
31. Yang X, Letterio JJ, Lechleider RJ, Chen L, Hayman R, Gu H et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta. EMBO J 1999; 18: 1280-1291
32. Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors alpha and beta in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996; 110: 975-984
33. Geremia A, Jewell DP. The IL-23/IL-17 pathway in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol 2012; 6: 223-237
34. O'Connor W Jr, Kamanaka M, Booth CJ, Town T, Nakae S, Iwakura Y et al. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 2009; 10: 603-609
35. Leppkes M, Becker C, Ivanov II, Hirth S, Wirtz S, Neufert C et al. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 2009; 136: 257-267